SUPPLEMENTARY DATA

Supplementary Table 1. Studies of patients with type 2 diabetes used in pooled analysis to obtain a population with 7-point glucose profiles before and after introduction of treatment with basal insulin (insulin glargine or comparator)

Study (No.)	Pre-study treatment regimen	Treatment comparator	*n*/*N* (%)*	Treatment duration
Gerstein et al 2006 (11) (3502)	0-2 OADs (no TZD) with ≥1 taken at or below ½ maximal dose	Insulin glargine	133/273 (48.7)	24 weeks
		OAD intensification	140/273 (51.3)	
Riddle et al 2003 (12) (4002)	Stable doses of 1 or 2 OADs (SU, MET, rosiglitazone, pioglitazone)	Insulin glargine	185/384 (48.2)	24 weeks
		NPH insulin	199/384 (51.8)	
Standl et al 2006 (13) (4009)	Uncontrolled on ≥1 OAD. During screening, previous OAD regimens were replaced with glimepiride 2, 3, or 4 mg	Insulin glargine (morning)/insulin glargine (bedtime)	378/378 (100)	24 weeks
Janka et al 2005 (14) (4027)	Stable doses of MET and SU. During screening, the SU was changed to glimepiride 3 or 4 mg	Insulin glargine	136/275 (49.5)	24 weeks
		NPH 70/30 insulin	139/275 (50.5)	
Bretzel et al 2008 (15) (4040)	Stable doses of ≥1 OAD (no alpha-glucosidase inhibitor) for ≥3 months	Insulin glargine	155/314 (49.4)	44 weeks
		Insulin lispro	159/314 (50.6)	
Yki-Järvinen et al 2006 (16) (6001)	Stable doses of MET and SU or MET alone for ≥3 months. SU was discontinued at randomization	Insulin glargine	39/75 (52)	36 weeks
		NPH insulin	36/75 (48)	
Overall		Insulin glargine	1026/1699 (60.4)	≥24 weeks
		Comparator	673/1699 (39.6)	

*Number of patients out of the subset of patients with complete 7-point glucose profile data at baseline and week 24. MET, metformin; OAD, oral antidiabetic drug; SU, sulfonylurea; TZD, thiazolidinedione.

SUPPLEMENTARY DATA

Supplementary Table 2. Incidence of hypoglycemia

	Symptomatic hypoglycemia	Glucose-confirmed symptomatic hypoglycemia*	Severe symptomatic hypoglycemia*
Basal insulin	750/1261 (59.5%)	374/1186 (31.5%)	14/1186 (1.2%)
Others	285/438 (65.1%)	185/438 (42.2%)	11/438 (2.5%)
Odds ratio (95% CI)	0.788 (0.628, 0.988)	0.630 (0.503, 0.789)	0.464 (0.209, 1.029)
P	0.0390	<0.0001	0.0589

*One of the studies (16) did not collect severity of glucose level for hypoglycemia events and thus were not included in the glucose-confirmed or severe hypoglycemia assessments.

Supplementary Figure 1. Depiction of the normal glycemic exposure (AUC_N), basal hyperglycemia (AUC_B), and postprandial hyperglycemia (AUC_P). The total area under the glucose curve is the sum of the above 3 measures [$AUC_N + AUC_B + AUC_P$].